These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Sorafenib induced eruptive melanocytic lesions.
    Author: Uhlenhake EE, Watson AC, Aronson P.
    Journal: Dermatol Online J; 2013 May 15; 19(5):18184. PubMed ID: 24011281.
    Abstract:
    Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepatocellular carcinoma. Dermatologic side effects include hand-foot skin reaction, facial and scalp erythema and desquamation, splinter subungual hemorrhages, alopecia, pruritus, xerosis, keratoacanthomas, and squamous cell carcinomas. We report sudden eruption of melanocytic nevi diffusely in a patient receiving sorafenib.
    [Abstract] [Full Text] [Related] [New Search]